REGENERON PHARMACEUTICALS, INC. (REGN) Cash and securities
- Total cash · latest quarter (USD): Value $7.99B; Formula and calculation Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30..
- Cash per share · latest quarter: Value (m); Formula and calculation Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30..
Cash and securities
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total cash · latest quarter (USD) | $7.99B | Cash and cash equivalents plus current marketable securities. Period ending 2026-06-30. $2.46B + $5.54B ≈ $7.99B |
| Cash per share · latest quarter | (m) | Cash and cash equivalents plus current marketable securities / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash and equivalents | 2.46B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 5.54B USD | Marketable Securities, Current |
| Cash and current securities | 7.99B USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total cash | Cash per share | Cash and equivalents (USD) | Short-term securities (USD) | Quarter-end shares (shares) |
|---|---|---|---|---|---|
| 2026-06-30 | $7.99B | (m) | $2.46B | $5.54B | (m) |
| 2026-03-31 | $8.75B | (m) | $2.96B | $5.79B | (m) |
| 2025-12-31 | $8.61B | (m) | $3.12B | $5.49B | (m) |
| 2025-09-30 | $8.44B | (m) | $2.51B | $5.94B | (m) |
| 2025-06-30 | $7.47B | (m) | $2.00B | $5.47B | (m) |
| 2025-03-31 | $8.35B | (m) | $3.09B | $5.26B | (m) |
| 2024-12-31 | $9.01B | (m) | $2.49B | $6.52B | (m) |
| 2024-09-30 | $9.80B | (m) | $2.01B | $7.78B | (m) |
| 2024-06-30 | $9.81B | (m) | $1.92B | $7.89B | (m) |
| 2024-03-31 | $10.52B | (m) | $2.60B | $7.92B | (m) |
| 2023-12-31 | $10.84B | (m) | $2.73B | $8.11B | (m) |
| 2023-09-30 | $9.91B | (m) | $2.15B | $7.76B | (m) |
| 2023-06-30 | $8.93B | (m) | $1.94B | $6.99B | (m) |
| 2023-03-31 | $8.96B | (m) | $3.92B | $5.04B | (m) |
| 2022-12-31 | $7.74B | (m) | $3.11B | $4.64B | (m) |
| 2022-09-30 | $7.02B | (m) | $3.49B | $3.53B | (m) |
| 2022-06-30 | $7.57B | (m) | $3.40B | $4.17B | (m) |
| 2022-03-31 | $7.05B | (m) | $3.35B | $3.70B | (m) |
| 2021-12-31 | $5.69B | (m) | $2.89B | $2.81B | (m) |
| 2021-09-30 | $5.79B | (m) | $3.43B | $2.36B | (m) |
| 2021-06-30 | $3.91B | (m) | $2.07B | $1.84B | (m) |
| 2021-03-31 | $3.50B | (m) | $1.44B | $2.07B | (m) |
| 2020-12-31 | $3.59B | (m) | $2.19B | $1.39B | (m) |
| 2020-09-30 | $3.03B | (m) | $1.57B | $1.45B | (m) |
| 2020-06-30 | $3.14B | (m) | $1.99B | $1.15B | (m) |
| 2020-03-31 | $4.00B | (m) | $2.21B | $1.80B | (m) |
| 2019-12-31 | $3.21B | (m) | $1.62B | $1.60B | (m) |
| 2019-09-30 | $2.88B | (m) | $1.38B | $1.49B | (m) |
| 2019-06-30 | $2.67B | (m) | $1.05B | $1.62B | (m) |
| 2019-03-31 | $3.23B | (m) | $1.71B | $1.52B | (m) |
| 2018-12-31 | $2.81B | (m) | $1.47B | $1.34B | (m) |
| 2018-09-30 | $2.19B | (m) | $1.09B | $1.10B | (m) |
| 2018-06-30 | $1.68B | (m) | $917.88M | $765.64M | (m) |
| 2018-03-31 | $1.62B | (m) | $1.02B | $605.46M | (m) |
| 2017-12-31 | $1.41B | (m) | $812.73M | $596.85M | (m) |
| 2017-09-30 | $1.38B | (m) | $792.07M | $586.88M | (m) |
| 2017-06-30 | $1.27B | (m) | $744.31M | $523.54M | (m) |
| 2017-03-31 | $1.31B | (m) | $811.77M | $495.31M | (m) |
| 2016-12-31 | $1.04B | (m) | $535.20M | $503.48M | (m) |
| 2016-09-30 | $1.41B | (m) | $920.36M | $488.03M | (m) |
| 2016-06-30 | $1.05B | (m) | $646.51M | $398.66M | (m) |
| 2016-03-31 | $849.18M | (m) | $604.21M | $244.97M | (m) |
| 2015-12-31 | $1.05B | (m) | $809.10M | $236.12M | (m) |
| 2015-09-30 | $895.64M | (m) | $654.59M | $241.06M | (m) |
| 2015-06-30 | $604.25M | (m) | $390.55M | $213.69M | (m) |
| 2015-03-31 | $742.16M | (m) | $507.91M | $234.26M | (m) |
| 2014-12-31 | $900.48M | (m) | $648.72M | $251.76M | (m) |
| 2014-09-30 | $1.04B | (m) | $646.55M | $395.65M | (m) |
| 2014-06-30 | $816.91M | (m) | $600.13M | $216.77M | (m) |
| 2014-03-31 | $648.13M | (m) | $461.86M | $186.28M | (m) |
| 2013-12-31 | $693.98M | (m) | $535.61M | $158.38M | (m) |
| 2013-09-30 | $445.32M | (m) | $263.21M | $182.11M | (m) |
| 2013-06-30 | $537.51M | (m) | $381.68M | $155.83M | (m) |
| 2013-03-31 | $307.71M | (m) | $180.36M | $127.35M | (m) |
| 2012-12-31 | $308.10M | (m) | $230.28M | $77.82M | (m) |
| 2012-09-30 | $262.55M | (m) | $119.00M | $143.55M | (m) |
| 2012-06-30 | $301.02M | (m) | $171.94M | $129.08M | (m) |
| 2012-03-31 | $432.30M | (m) | $394.58M | $37.71M | (m) |
| 2011-12-31 | $526.94M | (m) | $483.61M | $43.33M | (m) |
| 2011-09-30 | $245.50M | (m) | $206.40M | $39.10M | (m) |
| 2011-06-30 | $309.68M | (m) | $254.31M | $55.37M | (m) |
| 2011-03-31 | $226.44M | (m) | $135.38M | $91.06M | (m) |
| 2010-12-31 | $249.37M | (m) | $112.57M | $136.80M | (m) |
| 2010-09-30 | $479.05M | (m) | $325.29M | $153.77M | (m) |
| 2010-06-30 | $306.34M | (m) | $112.00M | $194.34M | (m) |
| 2010-03-31 | (m) | (m) | $117.31M | (m) | (m) |
| 2009-12-31 | $341.33M | (m) | $207.07M | $134.25M | (m) |
| 2009-09-30 | (m) | (m) | $250.32M | (m) | (m) |
| 2009-06-30 | (m) | (m) | $271.47M | (m) | (m) |
| 2008-12-31 | (m) | (m) | $247.80M | (m) | (m) |
| 2007-12-31 | (m) | (m) | $498.93M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |